Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + camrelizumab + SOX
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
Apatinib + camrelizumab + SOX is a combination regimen consisting of three agents: **apatinib** (a small molecule vascular endothelial growth factor receptor-2 [VEGFR-2] tyrosine kinase inhibitor), **camrelizumab** (a programmed cell death protein 1 [PD-1] monoclonal antibody immune checkpoint inhibitor), and **SOX**, a chemotherapy regimen composed of **S-1** (oral fluoropyrimidine) and **oxaliplatin** (platinum-based chemotherapeutic). This combination has been studied primarily as first-line or neoadjuvant treatment in **locally advanced, advanced, or metastatic gastric cancer or gastroesophageal junction cancer** (AGC/GEJC). Apatinib inhibits tumor angiogenesis and reverses multidrug resistance; camrelizumab enhances antitumor immune response by blocking PD-1; SOX impairs DNA synthesis and repair in rapidly dividing tumor cells. The combination has demonstrated high objective response rates and manageable safety in clinical trials for gastric cancer, though it is not an approved fixed-combination drug but an investigational regimen assembled from its individual components[1][3][7][9].
- Brand names
- AiRuiKa (for camrelizumab)Aitan (for apatinib)
- Other names
- apatinib + camrelizumab + SOXSOX plus apatinib and camrelizumab
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on apatinib + camrelizumab + SOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + camrelizumab + SOX.